JP6649376B2 - 肺の炎症を治療する方法 - Google Patents

肺の炎症を治療する方法 Download PDF

Info

Publication number
JP6649376B2
JP6649376B2 JP2017519463A JP2017519463A JP6649376B2 JP 6649376 B2 JP6649376 B2 JP 6649376B2 JP 2017519463 A JP2017519463 A JP 2017519463A JP 2017519463 A JP2017519463 A JP 2017519463A JP 6649376 B2 JP6649376 B2 JP 6649376B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
disease
composition according
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017519463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524732A5 (OSRAM
JP2017524732A (ja
Inventor
ベリンカ，ベンジャミン
カクラニ，スコット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017524732A publication Critical patent/JP2017524732A/ja
Publication of JP2017524732A5 publication Critical patent/JP2017524732A5/ja
Application granted granted Critical
Publication of JP6649376B2 publication Critical patent/JP6649376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017519463A 2014-06-20 2015-06-19 肺の炎症を治療する方法 Active JP6649376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014967P 2014-06-20 2014-06-20
US62/014,967 2014-06-20
PCT/US2015/036814 WO2015196159A1 (en) 2014-06-20 2015-06-19 Methods to treat inflammation of the lung

Publications (3)

Publication Number Publication Date
JP2017524732A JP2017524732A (ja) 2017-08-31
JP2017524732A5 JP2017524732A5 (OSRAM) 2018-07-26
JP6649376B2 true JP6649376B2 (ja) 2020-02-19

Family

ID=54868677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519463A Active JP6649376B2 (ja) 2014-06-20 2015-06-19 肺の炎症を治療する方法

Country Status (5)

Country Link
US (1) US9724384B2 (OSRAM)
EP (1) EP3157542B1 (OSRAM)
JP (1) JP6649376B2 (OSRAM)
CA (1) CA2952875C (OSRAM)
WO (1) WO2015196159A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4054662T (lt) * 2019-11-08 2024-08-12 Hollister Incorporated Hidrofiliniai medicinos produktai ir drėkinimo terpės jiems drėkinti

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199125B2 (en) * 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US8053406B2 (en) 2005-11-25 2011-11-08 University Of Medicine And Dentistry Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) * 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
WO2011047011A2 (en) 2009-10-13 2011-04-21 University Of Medicine And Dentistry Of New Jersey Treatment and diagnosis of inflammatory disorders
WO2012125942A1 (en) 2011-03-16 2012-09-20 University Of Medicine And Dentistry Of New Jersey Combination therapy with leukotoxin
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
US9950030B2 (en) * 2013-06-27 2018-04-24 Rutgers, The State University Of New Jersey Treatment and diagnosis of ocular disease

Also Published As

Publication number Publication date
CA2952875C (en) 2022-06-28
EP3157542A1 (en) 2017-04-26
US9724384B2 (en) 2017-08-08
EP3157542A4 (en) 2018-02-07
CA2952875A1 (en) 2015-12-23
US20150366937A1 (en) 2015-12-24
WO2015196159A1 (en) 2015-12-23
EP3157542B1 (en) 2024-12-25
JP2017524732A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
JP6031510B2 (ja) 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法
US20210070805A1 (en) Cd40 targeted peptides and uses thereof
KR20170083063A (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
CN111741763B (zh) 包含apl型肽的药用组合物
WO2021167883A1 (en) Method for treating asthma or allergic disease
CN107405405B (zh) 治疗和/或预防慢性阻塞性肺病的新组合物和方法
KR20160124236A (ko) 만성 폐 동종이식편 기능이상 및 특발성 폐 섬유증의 예방 또는 치료를 위한 조성물 및 방법
US20240261336A1 (en) Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
JP2016523913A (ja) 眼疾患の治療および診断
KR20170044171A (ko) 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
US9597368B2 (en) Peptide and uses therefor
JP6649376B2 (ja) 肺の炎症を治療する方法
Wang et al. Chimeric CNS-targeting-peptide engineered exosomes for experimental autoimmune encephalomyelitis therapy
JP2025000998A (ja) ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
JP2023504734A (ja) 制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法
CA3182210A1 (en) Methods and compositions for treating coronavirus infectious disease
EP3891179A1 (en) Methods and compositions for treating asthma
WO2024018442A1 (en) Preferential depletion of tcf1+ progenitor t-cells in severe covid-19 as mediated by interleukin 12 (il-12)
WO2025155743A1 (en) Chemokine ligand 18 (ccl18) for diagnosis and treatment of inflammatory lung disease
KR20130110225A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법
Fuhlbrigge et al. Children and asthma in America 2004 survey
Russell The role of macrophage migration inhibitory factor in airways disease
KR20080093016A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200116

R150 Certificate of patent or registration of utility model

Ref document number: 6649376

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250